AI is increasingly being adopted across healthcare and in 2025, it will be a driving force behind a smarter, nimbler, and ...

Large language models (LLMs) are poised to have a disruptive impact on health care. Numerous studies have demonstrated ...

Dosimetry is integral to informed implementation of radiopharmaceutical therapies, enabling personalized treatment planning ...

Arcus Biosciences, Inc. (NASDAQ:NYSE:RCUS), a biotechnology company focused on developing innovative cancer therapies, is navigating a critical phase in its development pipeline. With several key ...

In patients with high comorbidity burden that receive EVT for MCA medium-vessel occlusion there are worse clinical outcomes.

Researchers at the Indian Institute of Technology, Guwahati, in partnership with leading institutions around the world, have ...

AI was a key theme at OCT Medical Devices 2025, yet human sensibility appears to be the true differentiator in clinical trial ...

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

Panelists discuss how the landmark COMFORT trials have shaped the understanding of Janus kinase inhibitor therapy response criteria and long-term clinical outcomes in patients with myelofibrosis, ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two or three is ending early due to robust positive evidence found in previous ...

For over two decades, Citeline’s Trialtrove and Sitetrove have been trusted by clinical trial professionals worldwide to power smarter decisions with unparalleled ...

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...